An ensemble learning based framework to estimate warfarin maintenance dose with cross-over variables exploration on incomplete data set
暂无分享,去创建一个
Yu Wang | Fei Gao | Yan Liu | Jian Zhang | Ajing Xu | Jihui Chen | Yin You | Ping Li | Jiaxing Sun | Ze Yu | Yan Liu | Jian Zhang | A. Xu | Fei Gao | Ze Yu | Yin You | Jiaxing Sun | Jihui Chen | Ping Li | Yu Wang
[1] T. Bohnert,et al. Mechanism of Drug-Drug Interactions Between Warfarin and Statins. , 2016, Journal of pharmaceutical sciences.
[2] Daniel M. Witt,et al. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism , 2016, Journal of Thrombosis and Thrombolysis.
[3] Hang Xu,et al. Comparison of the Performance of the Warfarin Pharmacogenetics Algorithms in Patients with Surgery of Heart Valve Replacement and Heart Valvuloplasty. , 2015, Thrombosis research.
[4] Tianqi Chen,et al. XGBoost: A Scalable Tree Boosting System , 2016, KDD.
[5] M. Kinirons,et al. Drug metabolism and ageing. , 2004, British journal of clinical pharmacology.
[6] Jerzy W. Grzymala-Busse,et al. A Comparison of Several Approaches to Missing Attribute Values in Data Mining , 2000, Rough Sets and Current Trends in Computing.
[7] Christine W. Duarte,et al. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans , 2011, Bioinform..
[8] Houshang Darabi,et al. A New Approach towards Minimizing the Risk of Misdosing Warfarin Initiation Doses , 2018, Comput. Math. Methods Medicine.
[9] Massimo Buscema,et al. Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. , 2014, Pharmacogenomics.
[10] George Hripcsak,et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. , 2013, Medical care.
[11] Houshang Darabi,et al. Revisiting Warfarin Dosing Using Machine Learning Techniques , 2015, Comput. Math. Methods Medicine.
[12] Gang Zhang,et al. An Ensemble Learning Based Framework for Traditional Chinese Medicine Data Analysis with ICD-10 Labels , 2015, TheScientificWorldJournal.
[13] Tie-Yan Liu,et al. LightGBM: A Highly Efficient Gradient Boosting Decision Tree , 2017, NIPS.
[14] Jie Chen,et al. Warfarin maintenance dose Prediction for Patients undergoing heart valve replacement— a hybrid model with genetic algorithm and Back-Propagation neural network , 2018, Scientific Reports.
[15] R. Akdemir,et al. Use of neutrophil‐lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study , 2018, Clinical cardiology.
[16] Jacques Turgeon,et al. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy , 2015, Therapeutic drug monitoring.
[17] Ting Hsiang Lin,et al. A comparison of multiple imputation with EM algorithm and MCMC method for quality of life missing data , 2010 .
[18] Stef van Buuren,et al. MICE: Multivariate Imputation by Chained Equations in R , 2011 .
[19] R. Altman,et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.
[20] E N Jonsson,et al. A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy , 2007, Clinical pharmacology and therapeutics.
[21] P. Makarawate,et al. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients , 2017, European Journal of Clinical Pharmacology.
[22] Heather N. Watson,et al. Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data , 2011, Clinical epidemiology.
[23] Jie Chen,et al. Use of artificial neural network to predict warfarin individualized dosage regime in Chinese patients receiving low-intensity anticoagulation after heart valve replacement. , 2014, International journal of cardiology.
[24] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[25] Wei Zhang,et al. Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. , 2015, Pharmacogenomics.
[26] P. Deloukas,et al. A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age , 2010, Clinical pharmacology and therapeutics.
[27] Koroush Khalighi,et al. Clinical Model for Predicting Warfarin Sensitivity , 2019, Scientific Reports.
[28] Jason C. Fish,et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.
[29] M. Yalçın,et al. Neutrophil–Lymphocyte Ratio May Predict Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation , 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[30] P. Waterworth,et al. Inpatient Oral Anticoagulation Management by Clinical Pharmacists: Safety and Cost effectiveness , 2010, Journal of clinical medicine research.
[31] N. Takahashi,et al. We should pay more attention to renal function before initiation of warfarin therapy. , 2015, Journal of cardiology.
[32] F. Kamali,et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin , 2004, Clinical pharmacology and therapeutics.
[33] Josiah Poon,et al. Attention-based Multi-instance Neural Network for Medical Diagnosis from Incomplete and Low Quality Data , 2019, 2019 International Joint Conference on Neural Networks (IJCNN).
[34] R. Giugliano,et al. Oral Anticoagulation in Patients With Liver Disease. , 2018, Journal of the American College of Cardiology.
[35] W. Ageno,et al. Warfarin interactions with antibiotics in the ambulatory care setting. , 2014, JAMA internal medicine.
[36] Munir Pirmohamed,et al. A multi-factorial analysis of response to warfarin in a UK prospective cohort , 2016, Genome Medicine.
[37] Anna Veronika Dorogush,et al. CatBoost: unbiased boosting with categorical features , 2017, NeurIPS.
[38] Ken P Kleinman,et al. Much Ado About Nothing , 2007, The American statistician.
[39] Feng Yu,et al. Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement , 2017, Acta Pharmacologica Sinica.
[40] M. Rieder,et al. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.